Health, Fitness and Style

As of 2019, Medicare beneficiaries enrolled in Part D prescription drug plans will no longer be exposed to a coverage gap, sometimes called the “donut hole”, when they fill their brand-name medications. The coverage gap was included in the initial design of the Part D drug benefit in the Medicare Modernization Act of 2003 in order to reduce the total 10-year cost of the benefit. Subsequent legislative changes are phasing out the coverage gap by modifying the share of total costs paid in the gap by Part D enrollees and plans and requiring drug manufacturers to provide a discount on the price of brand-name drugs in the gap. more »

The Office of Environmental Health Hazard Assessment (OEHHA); the state of California's "mission is to protect and enhance public health and the environment by scientific evaluation of risks posed by hazardous substances." A couple of reports currently on the website: Protecting Public Health from Home and Building Fire Ash and Art and Craft Material Exposures and Impacts to Children's Health; Inorganic Arsenic in White and Brown Rice. more »

Some Retraction Watch Items: A star may not be quite as bright, but an astronomer deserves a gold star for retracting his findings within 24 hours of posting them and thanking those that helped him find the error. A study “asked whether the top scientific journals, Nature and Science, represented men and women equally as authors, subjects, and objects in photographs. Overwhelmingly, women were underrepresented in these magazines, an effect that was apparent even in advertisements and stock photographs.” “A scientific paper can mislead,” says Andrew Gelman. “People can read a paper, or see later popularizations of the work, and think that ‘science shows’ something that science didn’t show.” more »

Purdue’s 1996-2002 marketing plans for OxyContin, which Kaiser Health News made public this year for the first time, offer an unprecedented look at how that company spent millions of dollars to push opioids for growing legions of pain sufferers. Some of those drugmakers’ sales promotions downplayed or ignored the risks of taking opioids, or made false claims about their safety, federal regulators have asserted in warning letters to the companies. A wave of lawsuits demanding reimbursement and accountability for the opioid crisis now ravaging communities has heightened awareness about how and when drug makers realized the potential dangers of their products. more »